Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience
Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used worldwide as part of combination antiretroviral therapy in infants and children to treat HIV infection. Dosing based on either weight or body surface area has been approved by the U.S. Food and Drug Administration (FDA)...
Saved in:
Main Authors: | Mina Nikanjam, Desiré Kabamba, Tim R. Cressey, David Burger, Francesca T. Aweek, Edward P. Acosta, Stephen A. Spector, Edmund V. Capparelli |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84866307391&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/51844 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience
by: Nikanjam M., et al.
Published: (2014) -
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine
by: Kulkanya Chokephaibulkit, et al.
Published: (2018) -
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine
by: Kulkanya Chokephaibulkit, et al.
Published: (2018) -
Developmental pharmacokinetic changes of lamivudine in infants and children
by: Adriana H. Tremoulet, et al.
Published: (2018) -
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
by: Wasana Prasitsuebsai, et al.
Published: (2018)